4D Molecular Therapeutics, Inc.
FDMT
$10.45
$0.111.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 383,560.87% | 230,194.59% | 605.88% | -99.84% | -99.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 383,560.87% | 230,194.59% | 605.88% | -99.84% | -99.89% |
| Cost of Revenue | 41.23% | 36.87% | 44.05% | 53.60% | 50.30% |
| Gross Profit | 16.01% | 23.42% | -43.98% | -87.83% | -87.72% |
| SG&A Expenses | -2.86% | 5.33% | 11.72% | 23.46% | 26.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.56% | 29.05% | 35.58% | 45.51% | 43.86% |
| Operating Income | 12.83% | 16.29% | -35.52% | -67.91% | -68.18% |
| Income Before Tax | 8.81% | 12.90% | -45.79% | -78.49% | -68.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.81% | 12.90% | -45.79% | -78.49% | -68.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.81% | 12.90% | -45.79% | -78.49% | -68.75% |
| EBIT | 12.83% | 16.29% | -35.52% | -67.91% | -68.18% |
| EBITDA | 13.31% | 16.72% | -36.58% | -70.27% | -70.57% |
| EPS Basic | 15.04% | 14.27% | -32.19% | -53.99% | -30.87% |
| Normalized Basic EPS | 16.32% | 15.64% | -30.81% | -53.98% | -30.87% |
| EPS Diluted | 15.04% | 14.27% | -32.19% | -53.99% | -30.87% |
| Normalized Diluted EPS | 16.32% | 15.64% | -30.81% | -53.98% | -30.87% |
| Average Basic Shares Outstanding | 9.82% | 7.40% | 10.08% | 17.50% | 28.65% |
| Average Diluted Shares Outstanding | 9.82% | 7.40% | 10.08% | 17.50% | 28.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |